Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject).~* Nonsmoker~* Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant~* If female and of childbearing potential and subjects agrees to employ adequate birth control measures (e. g. oral contraceptives, barrier method)~* Negative urine pregnancy test~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Pregnancy or Lactation~* Treatment with an investigational drug within three weeks prior to this trial~* Participation in an LPS trial within the last 6 weeks~* Smoking~* History of relevant cardiac arrhythmia~* Preexisting open or closed angle glaucoma~* History of Osteoporosis, Cushing´s syndrome, gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, hypertension, brain tumor or history of neurosurgery~* Systemic tuberculosis~* Hemorrhagic diathesis~* Relevant liver or kidney dysfunction~* Regular use of medication or abuse of alcohol unless considered clinically relevant~* Use of any medication within one week prior to the first trial day~* Symptoms of a clinically relevant illness in the 3 weeks before the first trial day~* Excessive sporting activities~* Rosacea~* Subjects on Monoamine oxidase inhibitors (should be stopped for at least two to three weeks before dihydrocodeine treatment is initiate)~* Known acute or active hepatic disease within the past 3 months~* A platelet count \< 100,000 x 106/L, prothrombin time \> 1.5, liver enzymes\> 3 times the upper normal limit~* Having received a vaccination up to 8 weeks before the trial

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Sterile isotonic saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).